ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

osavampator

Also written as “NBI-1065845”, “TAK-653” and “Osavampator”.

Its studies are mostly in Depressive Disorder, Major · Depressive Disorder · Depressive Disorder, Treatment-Resistant, led by 2 companies.

Drug pageOsavampator: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jan 15, 20259 company-led studies, 5 open or runningNext primary completion: Jul 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Neurocrine Biosciences85 open or runningphase 3since Jan 15, 2025Sep 9, 2015Jul 2027phase 3 · NCT06911112
Takedaits history only10 open or runningphase 2since Oct 13, 2017Oct 13, 2017none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Neurocrine Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Sep 9, 2015First study: phase 1 study in Depressive DisorderFirst studyNCT02561156 · 88 enrolled · United Kingdom
  2. Jan 2, 2019Phase 1 study in Healthy VolunteersNCT03792672 · 24 enrolled · Netherlands
  3. Nov 18, 2021Phase 2 study in Depressive Disorder, MajorNCT05203341 · 183 enrolled · United States, Bulgaria, Czechia and more
  4. Aug 6, 2023Named osavampatorINNProposed as its International Nonproprietary Name in WHO's List 129 · before, NBI-1065845, TAK-653
  5. Jan 15, 2025Phase 3 study in Depressive Disorder, MajorNCT06786624 · 200 planned · United States
  6. Mar 28, 2025Phase 3 study in Depressive Disorder, MajorNCT06911112 · 200 planned · United States, Bulgaria, Lithuania and more
  7. Apr 30, 20252 phase 3 studies in Depressive Disorder, MajorNCT06966401, NCT06963021
  8. Sep 19, 2025Phase 3 study in Depressive Disorder, MajorNCT07196501 · 550 planned · United States, Australia, Bulgaria and more

Ahead

  1. Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06963021
  2. Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06911112
  3. Jul 2027Primary completion: phase 3 study in Depressive Disorder, MajorNCT06786624
  4. Jul 2028Primary completion: phase 3 study in Depressive Disorder, MajorNCT07196501

TargetBeta

“Glutamate receptor ionotropic AMPA positive allosteric modulator”ChEMBL 37, by rule

Studies

All 8 Neurocrine Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07196501Depressive Disorder, Major · United States, Australia, Bulgaria and more3RecruitingJul 2028550
NCT06966401Depressive Disorder, Major · United States, Australia, Belgium and more3RecruitingMay 2029850
NCT06963021Depressive Disorder, Major · United States, Belgium, Canada and more3RecruitingJul 2027200
NCT06911112Depressive Disorder, Major · United States, Bulgaria, Lithuania and more3RecruitingJul 2027200
NCT06786624Depressive Disorder, Major · United States3RecruitingJul 2027200
NCT05203341Depressive Disorder, Major · United States, Bulgaria, Czechia and more2CompletedJan 10, 2024183
NCT03792672Healthy Volunteers · Netherlands1CompletedMay 15, 201924
NCT02561156Depressive Disorder · United Kingdom1CompletedSep 11, 201788

How it is read

Names in the registry

  • “NBI-1065845”, 5 entries
  • “TAK-653”, 3 entries
  • “Osavampator”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.